We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+6.2%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.34B
AUM Growth
+$16.6M
Cap. Flow
+$14.4M
Cap. Flow %
0.61%
Top 10 Hldgs %
72.44%
Holding
37
New
–
Increased
22
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$32.3M
2
INSM icon
Insmed
INSM
+$19.9M
3
SHPG
Shire pic
SHPG
+$7.63M
4
AIMT
Aimmune Therapeutics
AIMT
+$7.39M
5
CELG
Celgene Corp
CELG
+$6.84M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$60.5M
2
BIVV
Bioverativ Inc. Common Stock
BIVV
+$14.3M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$2.58M

Sector Composition

Rank Sector Weight
1 Healthcare 92.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
26
DELISTED
Exact Sciences
EXAS
$12.6M 0.54%
312,719
+1,843
+0.6% +$89.9K
DRNA
27
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.79M 0.2%
500,913
– –
VIRX
28
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.16M 0.14%
33,214
– –
ALIM
29
DELISTED
Alimera Sciences
ALIM
$3.1M 0.13%
200,920
– –
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
$1.18M 0.05%
29,500
– –
ACGN
31
DELISTED
Aceragen Inc
ACGN
$1.13M 0.05%
4,537
– –
CYTK icon
32
Cytokinetics
CYTK
$10.5B
$891K 0.04%
123,686
– –
OCGN icon
33
Ocugen
OCGN
$475M
$833K 0.04%
5,049
– –
TRVN
34
DELISTED
Trevena, Inc.
TRVN
$560K 0.02%
546
– –
SPHS
35
DELISTED
Sophiris Bio, Inc.
SPHS
$496K 0.02%
247,000
– –
MLNT
36
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$375K 0.02%
10,138
– –
BIVV
37
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-264,400
Closed -$14.3M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q1 2018 Portfolio in Review

As of Q1 2018, Palo Alto Investors held 37 positions worth $2.34B, up 0.71% from $2.32B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Trading was light in Q1 2018: portfolio turnover was 2.7%. Palo Alto Investors opened no new positions and exited 1, leaving the 37-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q1 2018, an estimated $32.3M increase.
  • Palo Alto Investors's biggest Q1 2018 reduction was Abiomed Inc, cutting an estimated $60.5M.
  • Palo Alto Investors fully exited Bioverativ Inc. Common Stock in Q1 2018, selling an estimated $14.3M.
  • Palo Alto Investors's ten largest holdings make up 72% of its $2.34B portfolio in Q1 2018.
  • Palo Alto Investors opened 0 new positions and closed 1 in Q1 2018.
  • Palo Alto Investors's portfolio value rose 0.71% quarter-over-quarter to $2.34B.

Based on Palo Alto Investors's 13F filing for Q1 2018, filed 15 May 2018.